Help Patients Overcome Hurdles With GLP-1 Agonists
February 2024
Rxs are rolling in for GLP-1 agonists...liraglutide (Victoza, etc), semaglutide (Ozempic, etc), dulaglutide (Trulicity), etc.
It’s partly because these injectable meds are a first-line option for type 2 diabetes in patients who also have certain medical conditions...such as heart or kidney disease.
Plus injectable semaglutide (Wegovy) or tirzepatide (Zepbound) seem to be the most effective Rxs for managing overweight or obesity.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote